Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report)’s share price shot up 1.7% during mid-day trading on Wednesday . The stock traded as high as $5.25 and last traded at $5.25. 1,000 shares were traded during trading, an increase of 22% from the average session volume of 818 shares. The stock had previously closed at $5.1620.
Starpharma Trading Down 8.4%
The firm’s fifty day moving average is $4.02 and its 200-day moving average is $3.12.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
Read More
- Five stocks we like better than Starpharma
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
